Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212–2224

Article  CAS  PubMed  Google Scholar 

Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84

Article  PubMed  Google Scholar 

Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20

Article  PubMed  Google Scholar 

Sasso M, Miette V, Sandrin L, et al. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol. 2012;36:13–20

Article  CAS  PubMed  Google Scholar 

Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1717–1730

Article  PubMed  Google Scholar 

Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497–509

Article  PubMed  Google Scholar 

Tosaki T, Kamiya H, Himeno T, et al. Sodium-glucose co-transporter 2 inhibitors reduce the abdominal visceral fat area and may influence the renal function in patients with type 2 diabetes. Intern Med. 2017;56:597–604

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–1031

Article  CAS  PubMed  Google Scholar 

Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21:285–292

Article  CAS  PubMed  Google Scholar 

de Ledinghen V, Vergniol J, Foucher J, et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911–918

Article  PubMed  Google Scholar 

Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254

Article  CAS  PubMed  Google Scholar 

Salmi A, di Filippo L, Ferrari C, et al. Ultrasound and FibroScan((R)) Controlled Attenuation Parameter in patients with MAFLD: head to head comparison in assessing liver steatosis. Endocrine. 2022;78:262–269

Article  CAS  PubMed  Google Scholar 

Ferraioli G. Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens). J Med Ultrason. 2001;2021(48):489–495

Google Scholar 

Zhou P, Tan Y, Hao Z, et al. Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1144838

Article  PubMed  Google Scholar 

Taheri H, Malek M, Ismail-Beigi F, et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther. 2020;37:4697–4708

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han E, Lee YH, Lee BW, et al. Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: a 24-week randomized controlled trial. J Clin Med. 2020;9:259–272

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical Trial. Diabetes Ther. 2021;12:843–861

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gu Y, Sun L, Zhang W, et al. Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: a GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1102792

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357

Article  PubMed  Google Scholar 

Hu C WY, Xi Y, Yao X. Dapagliflozin therapy curative effect observation on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Indian J Pharm Sci. 2020;82:122–129

CAS  Google Scholar 

Zelber-Sagi S, Webb M, Assy N, et al. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol. 2013;19:57–64

Article  PubMed  PubMed Central  Google Scholar 

Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol. 2022;7:367–378

Article  CAS  PubMed  Google Scholar 

Cho KY, Nakamura A, Omori K, et al. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J Diabetes Investig. 2020. https://doi.org/10.1111/jdi.13457

Article  PubMed  PubMed Central  Google Scholar 

Simental-Mendia M, Sanchez-Garcia A, Rodriguez-Ramirez M, et al. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2021;163: 105319

Article  CAS  PubMed  Google Scholar 

Lee HW, Kim KJ, Jung KS, et al. The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. PLoS ONE. 2017;12: e0187066

Article  PubMed  PubMed Central  Google Scholar 

ElMahdy MK, Helal MG, Ebrahim TM. Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-alpha, IL-1beta, and IL-18 in rat liver. Int Immunopharmacol. 2020;86: 106730

Article  CAS  PubMed  Google Scholar 

Li L, Li Q, Huang W, et al. Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway. Front Pharmacol. 2021;12: 589273

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin Z, Yin R, Yuan Y, et al. Dapagliflozin ameliorates hepatic steatosis via suppressing LXRalpha-mediated synthesis of lipids and bile acids. Biochem Pharmacol. 2024;223: 116167

Article  CAS  PubMed  Google Scholar 

Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(598–607): e2

Google Scholar 

Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–209

Article  PubMed  Google Scholar